Delayed Graft Function (DGF) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Delayed Graft Function (DGF) – Drugs In Development, 2024 report and make more profitable business decisions.
Delayed graft function (DGF) is an indication of acute kidney injury (AKI) occurring after a kidney transplant, with attributes unique to the transplant process. AKI is defined as an increase in serum creatinine within 48 hours of an inciting event. In the case of a transplant, the timing is less straightforward. The diagnosis of DGF is complicated by a variety of definitions based on a range of clinical criteria dependent on the local transplant center, region, country. DGF is a major obstacle for allograft survival as it can be compounded by acute rejection and chronic allograft nephropathy.
The Delayed Graft Function (DGF) drugs in development market research report provide comprehensive information on the therapeutics under development for Delayed Graft Function (DGF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Delayed Graft Function (DGF) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Delayed Graft Function (DGF) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 9 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Delayed Graft Function (DGF) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Delayed Graft Function (DGF) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Delayed Graft Function (DGF) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Argenx SEBalmes Transplantation SAS
Corline Biomedical AB
Ischemix Inc
Pharming Group NV
Proterris Inc
Quark Pharmaceuticals Inc
Unicyte AG
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Delayed Graft Function (DGF) reports